Key Takeaways of Contrast Media Injectors Market Study

• North America is expected to be the most lucrative region and account for more than 32% of revenue in the global contrast media injectors in 2020 and this trend is expected to continue during the forecast period
• Larger patient pool and increasing government support towards developing healthcare system in Asian countries are expected to propel the growth of the contrast media injectors market in the region
• AI is expected to speed up the process of injecting contrast media in the forecast period
• Increasing applications in orthopedic surgeries and neurosurgeries to bolster the market in the forecast period

“To remain ‘ahead’ of your competitors, request for a sample” 

Contrast Media Injectors Market Outlook & Key Findings

• Contrast media injectors market likely to grow at over 4.9 % through 2030
• The rising cost of contrast media injectors is expected to hamper the market growth as most small- and medium-sized hospitals cannot afford them
• Extensive research regarding biodegradable contrast media injectors to drive investment in the near future
• Unhealthy lifestyle to propagate the use of contrast media injectors in the upcoming period

Leading Players in Contrast Media Injectors Market

The contrast media injectors market players are trying out every possible mode of organic/inorganic growth to sustain themselves in the market. For instance – Windsong Radiology Group acquired MEDRAD Stellant FLEX Injection System to help both – Windsong and Bayer to avert downtime, standardize care, and minimize operational costs.

Shenzhen Anke High-tech Co. Ltd.’s single-head CT SCAN contrast media injector is endowed with injection interruption that facilitates flexible handling of emergencies. Contrast media injectors offered by Ulrich GmbH & Co. KG facilitate user-friendly handling and have been into the market since the last 3 decades with use in MRI and CT.

Get a Customized Scope to Match Your Need Ask an Expert- https://www.futuremarketinsights.com/ask-question/rep-gb-823

The above-mentioned players along with the others in the contrast media injectors market include:

Americas

• Mallinckrodt (Guerbet SA)
• GE Healthcare

Europe

• Bayer AG
• Ulrich GmbH & Co. KG
• Bracco Imaging S.p.A
• Medtron

Asia Pacific

• Nemoto Kyorindo Co. Ltd
• Shenzhen Anke High-tech Co. Ltd

*The list is only for representational purposes not exhaustive. Full competitive intelligence with SWOT analysis available in the report

New Product Launches and Approval – The Ongoing Trend

The market players are into getting their new products launched as well as approved to stay in the competition and also keep pace with the market scenario (that of continuing to innovate). The constructive steps in this regard are:

• In Apr 2020, Guerbet announced getting approved by the US FDA for manufacturing gadoterate meglumine (Dotarem) injection inside the US. Till late 2019, this production used to happen outside of the US.
• In Nov 2019, the US FDA approved an MRI contrast agent “Clariscan” for intravenous use in spine, brain (intracranial), and associated tissues.
• In Aug 2019, Bracco Diagnostics, Inc. announced getting approved by the US FDA for oral suspension of barium sulfate (Varibar Thin Liquid). The basic use of this contrast agent is detection and assessment of dysphagia.

What else is in the report?

Future market insights offer actionable insights and unique perspective on contrast media injectors market in its latest study, presenting historical demand assessment from 2015 – 2019 and projections from 2020–2030 based on product type (angiographic injectors, magnetic resonance imaging (MRI) injectors, computed tomography (CT) injectors), by end-user (hospital, ambulatory surgical centres, diagnostics centres) in seven key regions